FDA plots multi-day hearing to review 'dangling' accelerated approval that drugmaker refuses to pull

What happens when the FDA tells a company to pull a drug approved under its accelerated pathway because it didn’t prove to be effective in a confirmatory trial, and the company refuses?

That’s what is currently playing out between the FDA and Covis Pharma.